SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
For
the quarterly period ended
For the transition period from ___________ to ___________
Commission
file number
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices)
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company", and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Smaller
reporting company |
Emerging
Growth Company |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in 12b-2 of the Exchange Act):
Yes
☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The Stock Market LLC | ||||
| The Stock Market LLC |
As of May 22, 2023, the Company has shares of common stock issued and outstanding.
| 1 |
APPLIED UV, INC. & SUBSIDIARIES
INDEX TO FORM 10-Q
| Page # | |
| PART I - FINANCIAL INFORMATION | |
| Item 1. Consolidated Financial Statements (Unaudited) | |
| Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 | 3 |
| Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2023 and 2022 | 4 |
| Condensed Consolidated Statements of Redeemable Preferred Stock and Changes in Stockholders’ Equity for the Three Months Ended March 31, 2023 and 2022 | 5 |
| Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and 2022 | 6 |
| Notes to Condensed Consolidated Financial Statements | 7 |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | 35 |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | 43 |
| Item 4. Controls and Procedures | 43 |
| PART II - OTHER INFORMATION | |
| Item 1. Legal Proceedings | 44 |
| Item 1A. Risk Factors | 44 |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 44 |
| Item 3. Defaults Upon Senior Securities | 44 |
| Item 4. Mine Safety Disclosures | 44 |
| Item 5. Other Information | 44 |
| Item 6. Exhibits | 44 |
| Signatures | 45 |
| 2 |
PART I
Item 1. Financial Statements
Applied UV, Inc. and Subsidiaries
Unaudited Condensed Consolidated Balance Sheets
As of March 31, 2023 and December 31, 2022
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net of allowance for doubtful accounts | ||||||||
| Costs and estimated earnings in excess of billings | ||||||||
| Inventory, net | ||||||||
| Vendor deposits | ||||||||
| Prepaid expense and other current assets | ||||||||
| Total Current Assets | ||||||||
| Property and equipment, net of accumulated depreciation | ||||||||
| Other assets | ||||||||
| Goodwill | ||||||||
| Other intangible assets, net of accumulated amortization | ||||||||
| Right of use assets | ||||||||
| Total Assets | $ | $ | ||||||
| Liabilities and Stockholders' Equity | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued expenses | $ | $ | ||||||
| Contingent consideration | ||||||||
| Deferred revenue | ||||||||
| Due to landlord (Note 2) | ||||||||
| Warrant liability | ||||||||
| Financing lease obligations | ||||||||
| Operating lease liability | ||||||||
| Notes payable, net | ||||||||
| Total Current Liabilities | ||||||||
| Long-Term Liabilities | ||||||||
| Due to landlord - less current portion (Note 2) | ||||||||
| Notes payable, net - less current portion | ||||||||
| Financing lease obligations - less current portion | ||||||||
| Operating lease liability - less current portion | ||||||||
| Total Long-Term Liabilities | ||||||||
| Total Liabilities | ||||||||
| Redeemable Preferred Stock | ||||||||
| Preferred Stock, Series B Cumulative Perpetual, $par value, shares authorized, shares issued and outstanding as of March 31, 2023 and shares issued and outstanding as of December 31, 2022 | ||||||||
| Preferred Stock, Series C Cumulative Perpetual, $par value, shares authorized, shares issued and outstanding as of March 31, 2023 and shares issued and outstanding as of December 31, 2022 | ||||||||
| Total Redeemable Preferred Stock | ||||||||
| Equity | ||||||||
| Preferred Stock, Series A Cumulative Perpetual, $par value, shares authorized, shares issued and outstanding as of March 31, 2023 and December 31, 2022. | ||||||||
| Preferred Stock, Series X, $par value, shares authorized, shares issued and outstanding as of March 31, 2023 and December 31, 2022 respectively | ||||||||
| Common Stock $ par value, shares authorized shares issued and shares outstanding as of March 31, 2023 and shares issued and shares outstanding as of December 31, 2022 respectively | ||||||||
| Additional paid-in capital | ||||||||
| Treasury stock at cost, shares, respectively | ( | ) | ( | ) | ||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total Equity | ||||||||
| Total Liabilities, Redeemable Preferred Stock and Stockholders' Equity | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited interim consolidated financial statements.
| 3 |
Applied UV, Inc. and Subsidiaries
Unaudited Condensed Interim Consolidated Statements of Operations
For the Three Months Ended March 31, 2023 and 2022
| 2023 | 2022 | |||||||
| Net Sales | $ | $ | ||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research and development | ||||||||
| Selling General and Administrative Expenses | ||||||||
| Loss on impairment of goodwill and intangibles | ||||||||
| Total Operating Expenses | ||||||||
| Operating Loss | ( | ) | ( | ) | ||||
| Other Income (Expense) | ||||||||
| Change in Fair Market Value of Warrant Liability | ||||||||
| Interest expense | ( | ) | ( | ) | ||||
| Loss on change in Fair Market Value of Contingent Consideration | ( | ) | ( | ) | ||||
| Gain on Settlement of Contingent Consideration (Note 2) | ||||||||
| Total Other Income (Expense) | ( | ) | ||||||
| Loss Before Provision for Income Taxes | ( | ) | ( | ) | ||||
| Benefit from Income Taxes | ||||||||
| Net Loss | $ | ( | ) | $ | ( | ) | ||
| Net Loss attributable to common stockholders: | ||||||||
| Dividends to preferred shareholders | ( | ) | ( | ) | ||||
| Net Loss attributable to common stockholders | ( | ) | ( | ) | ||||
| Basic and Diluted Loss Per Common Share | $ | ( | ) | $ | ( | ) | ||
| Weighted Average Shares Outstanding - basic and diluted | ||||||||
The accompanying notes are an integral part of these unaudited interim consolidated financial statements.
| 4 |
Applied UV, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Redeemable Preferred Stock and Changes in Stockholders' Equity
For the Three Months Ended March 31, 2023 and 2022
Preferred Stock Series B | Preferred Stock Series C | Total Redeemable Preferred Stock | Preferred Stock Series A | Preferred Stock Series X | Common Stock | Treasury Stock | Additional Paid-In Capital | Accumulated Deficit | Total Stockholders Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, January 1, 2022 | $ | $ | $ | — | $ | $ | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Settlement of stock in connection with prior acquisition (Note 2) | — | — | — | — | — | — | ( | ) | ( | ) | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued for in public offering (over-allotment), net of costs | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends paid to preferred shareholders | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cancellation of restricted stock | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2022 | $ | $ | $ | — | $ | $ | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, January 1, 2023 | $ | $ | $ | — | $ | $ | $ | $ | ( | ) | $ | $ | ( | ) | $ | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common and Preferred stock issued for acquisition | 4,776,489 | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common stock issued in public offering (ATM), net of costs | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends paid to preferred shareholder | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net Loss | — | — | — | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2023 | $ | $ | $ | 4,776,489 | $ | 10,000 | $ | $ | $ | ( | ) | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited interim consolidated financial statements.
| 5 |
Applied UV, Inc. and Subsidiaries
Condensed Interim Consolidated Statements of Cash Flows
For the Three Months Ended March 31, 2023 and 2022
| 2023 | 2022 | |||||||
| Cash flows from Operating Activities | ||||||||
| Net Loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities | ||||||||
| Stock based compensation | ||||||||
| Bad debt (recovery) expense | ( | ) | ||||||
| Change in fair market value of warrant liability | ( | ) | ( | ) | ||||
| Loss on change in Fair Market Value of Contingent Consideration | ||||||||
| Gain on settlement of contingent consideration | ( | ) | ||||||
| Loss on impairment of goodwill and intangible assets | ||||||||
| Amortization of right-of-use asset | ||||||||
| Depreciation and amortization | ||||||||
| Amortization of debt discount | ||||||||
| Changes in operating assets and liabilities, net of effects of acquisitions: | ||||||||
| Accounts receivable | ( | ) | ||||||
| Cost and estimated earnings excess of billings | ( | ) | ( | ) | ||||
| Inventory | ( | ) | ||||||
| Vendor deposits | ( | ) | ||||||
| Prepaid expense and other current assets | ( | ) | ( | ) | ||||
| Other non-current assets | ||||||||
| Accounts payable and accrued expenses | ||||||||
| Billings in excess of costs and earnings on uncompleted contracts | ( | ) | ||||||
| Deferred revenue | ( | ) | ||||||
| Due to landlord | ( | ) | ||||||
| Operating lease payments | ( | ) | ( | ) | ||||
| Net Cash Used in Operating Activities | ( | ) | ( | ) | ||||
| Cash Flows From Investing Activities | ||||||||
| Cash paid for patent costs | ( | ) | ||||||
| Purchase of machinery and equipment | ( | ) | ( | ) | ||||
| Acquisitions, net of cash acquired (Note 2) | ( | ) | ( | ) | ||||
| Payments on note payable | ( | ) | ||||||
| Net Cash Used in Investing Activities | ( | ) | ( | ) | ||||
| Cash Flows From Financing Activities | ||||||||
| Payments on financing leases | ( | ) | ( | ) | ||||
| Dividends to preferred shareholders | ( | ) | ( | ) | ||||
| Payments on note payable | ( | ) | ||||||
| Proceeds from equity raises, net | ||||||||
| Proceeds from note payable, net | ||||||||
| Net Cash Provided by Financing Activities | ||||||||
| Net Decrease in Cash and equivalents | ( | ) | ( | ) | ||||
| Cash and cash equivalents at January 1, | ||||||||
| Cash and cash equivalents at December 31, | $ | $ | ||||||
| Supplemental Disclosures of Cash Flow Information: | ||||||||
| Cash paid during the year for: | ||||||||
| Interest | $ | $ | ||||||
| Income taxes | $ | $ | ||||||
| Supplemental Non-Cash Items of Investing and Financing Activities: | ||||||||
| Recognition of right of use asset and corresponding lease liability | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited interim consolidated financial statements.
| 6 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Business
Applied UV, Inc. (the "Parent") was formed and incorporated in the State of Delaware for the intended purpose of holding the equity of SteriLumen, Inc. (“SteriLumen”), MunnWorks, LLC (“MunnWorks” and together with SteriLumen, the “Subsidiaries”) and other companies acquired or created by the Parent in the future. The Parent acquired the Subsidiaries pursuant to three share exchanges whereby the equity holders of the Subsidiaries exchanged all of their equity interests in the Subsidiaries for shares of voting stock of the Parent. As a result of the share exchanges, each Subsidiary became a wholly-owned subsidiary of the Parent. The Parent and each Subsidiary are collectively referred to herein as (the "Company").
SteriLumen is engaged in the design, manufacture, assembly and distribution of (i) automated disinfecting mirror systems for use in hospitals and other healthcare facilities and (ii) air purification and pathogen elimination systems through its purchase of substantially all of the assets and certain liabilities of Akida Holdings, LLC, KES Science & Technology, and Scientific Air Management LLC, as described below. MunnWorks, LLC is engaged in the manufacture of fine mirrors and custom furniture specifically for the hospitality and retail industries.
On March 25, 2022, the Company acquired the assets and assumed certain liabilities of VisionMark, LLC, ("VisionMark"). VisionMark is engaged in the business of manufacturing furniture using wood and metal components for the hospitality and retail industries.
On January 26, 2023 we closed on the merger agreement with PURO Lighting LLC and LED Supply Co. LLC along with its operating subsidiaries (“PURO merger”). PURO and LED Supply Co. own a powerful suite of products used in education, government, and healthcare that incorporates UV Lighting and a HVAC monitoring software platform; LED Supply Co. provides design, distribution, and implementation services for lighting, controls and smart building technologies.
Principles of Consolidation
The consolidated financial statements include the accounts of Applied UV, Inc., MunnWorks, LLC and SteriLumen, Inc. All significant intercompany transactions and balances are eliminated in consolidation.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) set forth in Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of the results for the full fiscal year. These financial statements should be read along with the Annual Report filed of the Company for the annual period ended December 31, 2022. The consolidated balance sheet as of December 31, 2022 was derived from the audited consolidated financial statements as of and for the year then ended.
| 7 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Concentration of Credit and Business Risk
At
times throughout the year, the Company maintains cash balances at various institutions, which may exceed the Federal Deposit Insurance
Corporation limit. As of March 31, 2023, the Company was approximately $
For the three months ended March 31, 2023 and 2022, the Company had no major suppliers that accounted for over 10% of supplies and materials used by the Company.
Use of Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, as of the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the valuation and accounting for equity awards related to warrants and stock-based compensation, determination of fair value for derivative instruments, the accounting for business combinations and allocating purchase price and estimating the useful life of intangible assets.
Cash, Restricted Cash and Cash Equivalents
Cash
and equivalents include highly liquid investments that have original maturities less than 90 days at the time of their purchase. These
investments are carried at cost, which approximates market value because of their short maturities. As of March 31, 2023 and December
31, 2022, the Company had approximately $
Accounts receivable
The
Company’s accounts receivable balance consists of amounts due from its customers. The Company records accounts receivable at the
invoiced amount less an allowance for any potentially uncollectable accounts under the current expected credit loss (“CECL”)
impairment model and presents the net amount of the financial instrument expected to be collected. The CECL impairment model requires
an estimate of expected credit losses, measured over the contractual life of an instrument, which considers forecasts of future economic
conditions in addition to information about past events and current conditions. Based on this model, the Company considers many factors,
including the age of the balance, collection history, and current economic trends. Bad debts are written off after all collection efforts
have ceased. Allowances for credit losses are recorded as a direct reduction from an asset’s amortized cost basis. Credit losses
and recoveries are recorded in selling, general and administrative expenses in the consolidated statements of operations. Recoveries
of financial assets previously written off are recorded when received. For the three months ended March 31, 2023 and 2022, the Company
had credit losses (recoveries) of $ (
| 8 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Inventory
Inventories
consist of raw materials, work-in-process, and finished goods. Raw materials and finished goods are valued at the lower of cost or net
realizable value, using the first-in, first-out (“FIFO”) valuation method. Work-in-process and finished goods includes the
cost of materials, freight and duty, direct labor and overhead. The Company writes down inventory for estimated obsolescence equal to
the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions.
The company had a reserve for inventory approximating $
Property and Equipment
Property and equipment are recorded at cost. Depreciation of furniture and fixtures is provided using the straight-line method, generally over the terms of the lease. Repairs and maintenance expenditures, which do not extend the useful lives of the related assets, are expensed as incurred. Depreciation of machinery and equipment is based on the estimated useful lives of the assets.
| Schedule of estimated useful lives | ||
| Machinery and equipment | ||
| Leasehold improvements | ||
| Furniture and fixtures |
Business Acquisition Accounting
The Company applies the acquisition method of accounting for those that meet the criteria of a business combination. The Company allocates the purchase price of its business acquisitions based on the fair value of identifiable tangible and intangible assets. The difference between the total cost of the acquisition and the sum of the fair values of acquired tangible and identifiable intangible assets less liabilities is recorded as goodwill. Transaction costs are expensed as incurred in general and administrative expenses.
Goodwill and Intangible Assets
The Company has recorded intangible assets, including goodwill, in connection with business combinations. Estimated useful lives of amortizable intangible assets are determined by management based on an assessment of the period over which the asset is expected to contribute to future cash flows.
In accordance with U.S. GAAP for goodwill and other indefinite-lived intangibles, the Company tests these assets for impairment annually and whenever events or circumstances make it more likely than not that impairment may have occurred. For the purposes of that assessment, the Company has determined to assign assets acquired in business combinations to a single reporting unit including all goodwill and indefinite-lived intangible assets acquired in business combinations.
| 9 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
Income Taxes
The Company files income tax returns using the cash basis of accounting. Income taxes are accounted for under the asset and liability method. Current income taxes are based on the year's income taxable for federal and state tax
reporting purposes. Deferred income tax assets and liabilities are computed annually for differences between the financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable income will be available to allow all or part of the asset to be recovered.
Derivative Instruments
The Company evaluates its warrants to determine if those contracts or embedded components of those contracts qualify as derivatives. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statements of operations as other income or expense.
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. The Company has concluded that there are no such reclassifications required to be made as of and for the periods ended March 31, 2023 and December 31, 2022.
The Company utilizes the Black-Scholes valuation model to value the derivative warrants as stipulated in the agreement for the warrant holders to receive cash based on that value.
Fair Value of Financial Instruments
The carrying amounts reported in the unaudited condensed consolidated balance sheets for loans payable approximate fair value because of the immediate or short-term maturity of the financial instruments. The Company's financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy.
Basic loss per share is computed by dividing net loss attributable to common shareholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period. In periods of losses, diluted loss per share is computed on the same basis as basic loss per share as the inclusion of any other potential shares outstanding would be anti-dilutive.
The following table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share because their effect was anti-dilutive:
Schedule of Anti-dilutive Securities Excluded from Computation of Loss Per Share:
| Schedule of anti dilutive securities excluded from computation of earnings per share | ||||||||
| As of March 31, | ||||||||
| 2023 | 2022 | |||||||
| Common stock options | ||||||||
| Series B Preferred Stock | ||||||||
| Series C Preferred Stock | ||||||||
| Common stock warrants | ||||||||
| Total | ||||||||
| 10 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
The Company accounts for its stock-based compensation awards in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic 718 ("ASC"), Compensation-Stock Compensation ("ASC 718"). ASC 718 requires all stock-based payments to employees, including grants of employee stock options and restricted stock and modifications to existing stock options, to be recognized in the statements of operations based on their fair values over the requisite service period.
Research and Development
The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, research and development costs are expensed as incurred.
Revenue Recognition
The Company recognizes revenue when the performance obligations in the client contract has been achieved. A performance obligation is a contractual promise to transfer product to the customer. The transaction price of a contract is allocated to each distinct performance obligation and recognized as revenue when or as, the customer receives the benefit of the performance obligation. Under ASC 606, revenue is recognized when a customer obtains control of goods in an amount that reflects the consideration the Company expects to receive in exchange for those goods. To achieve this core principle, the Company applies the following five steps:
| 1) | Identify the contract with a customer. |
| 2) | Identify the performance obligations in the contract. |
| 3) | Determine the transaction price. |
| 4) | Allocate the transaction price to performance obligations in the contract. |
| 5) | Recognize revenue when or as the Company satisfies a performance obligation. |
MunnWorks projects, including those from the VisionMark acquisition, are completed within the Company’s facilities. For these projects, the company designs, manufactures and sells custom mirrors and furniture for the hospitality and retail industries through contractual agreements. These sales require the company to deliver the products within three to nine months from commencement of order acceptance. Revenue is recognized using the input method of accounting. Deferred revenue represents amounts billed in excess of revenues recognized. Revenues recognized in excess of amounts billed typically does not occur as the Company will not perform any work in excess of the amount the company bills to its customers. If work is performed in excess of amounts billed, the Company will record an unbilled receivable.
| 11 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Revenue Recognition (Continued)
The company applied the five-step model to the sales of PURO's disinfection solution, LED's lighting products, Akida’s and KES’s Airocide™ and misting system products, and SciAir’s whole-room aerosol chamber and laboratory certified air disinfection machines. At contract inception and once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company sells Airocide™ air sterilization units, misting systems, and whole-room aerosol chamber and laboratory certified disinfection machines to both consumer and commercial customers. These products are sold both domestically and internationally. The cycle from contract inception to shipment of products is typically one day to three months. The Company’s contracts for both its consumer and commercial customers each contain a single performance obligation (delivery of Airocide™, KES, and SciAir products), as the promise to transfer the individual goods or services is not separately identifiable from other promises in the contracts and, therefore, not distinct. As a result, the entire transaction price is allocated to this single performance obligation. The Company recognizes revenues at a point in time when the customer obtains control of the Company’s product, which typically occurs upon shipment of the product by the Company or upon customer pick-up via third party common carrier.
Revenue recognized over time and revenue recognized at a point in time for the three months ended:
Schedule of revenue:
| Schedule of revenue | ||||||||
| March 31, | ||||||||
| 2023 | 2022 | |||||||
| Recognized over time | $ | $ | ||||||
| Recognized at a point in time | ||||||||
| $ | $ | |||||||
Deferred revenue was comprised of the following as of:
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Recognized over time | $ | $ | ||||||
| Recognized at a point in time | ||||||||
| $ | $ | |||||||
The
Company recognized $
Advertising
Advertising
costs consist primarily of online search advertising and placement, trade shows, advertising fees, and other promotional expenses. Advertising
costs are expensed as incurred and are included in sales and marketing on the consolidated statements of operations. Advertising expense
for the three months ended March 31, 2023 and 2022 was $
Vendor deposits
Vendor
payments to third manufactures are capitalized until completion of the project and are recorded as vendor deposits. As of March 31, 2023
and December 31, 2022, the vendor deposit balance was $
| 12 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Patent Costs
The
Company capitalizes costs consisting principally of outside legal costs and filing fees related to obtaining and maintaining patents.
The Company amortizes patent costs over the useful life of the patent which is typically 20 years, beginning with the date the patent
is filed with the U.S. Patent and Trademark Office, or foreign equivalent. As of March 31, 2023 and December 31, 2022, capitalized patent
costs net of accumulated amortization was $
Recently adopted accounting standards:
From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2023. These standards replace the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measure at amortized cost to be presented at the net amount expected to be collected. The Company determined that this change does not have a material impact to the financial statements or financial statement disclosures.
Recently issued accounting pronouncements:
In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470 20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815 40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if converted method for all convertible instruments. The amendments in this update will be effective for the Company on January 1, 2024 and may be early adopted at the beginning of fiscal year 2023. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.
NOTE 2 – BUSINESS ACQUISITION
The Company accounted for the acquisitions as a business combinations using the purchase method of accounting as prescribed in Accounting Standards Codification 805, Business Combinations (“ASC 805”) and ASC 820 – Fair Value Measurements and Disclosures (“ASC 820”). In accordance with ASC 805 and ASC 820, the Company used its best estimates and assumptions to accurately assign fair value to the tangible assets acquired, identifiable intangible assets and liabilities assumed as of the acquisition dates. Goodwill as of the acquisition date is measured as the excess of purchase consideration over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed. The results of operations of the acquired businesses since the date of acquisition are included in the consolidated financial statements of the Company for the three months ended March 31, 2023 and 2022. The total purchase consideration was allocated to the assets acquired and liabilities assumed at their estimated fair values as of the date of acquisition, as determined by management. The excess of the purchase price over the amounts allocated to assets acquired and liabilities assumed has been recorded as goodwill. The value of the goodwill from the acquisitions described below can be attributed to a number of business factors including, but not limited to, cost synergies expected to be realized and a trained technical workforce.
| 13 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 2 – BUSINESS ACQUISITION (CONTINUED)
In conjunction with acquisitions noted below, we used various valuation techniques to determine fair value of the assets acquired, with the primary techniques being discounted cash flow analysis, relief-from-royalty, a form of the multi-period excess earnings and the with-and-without valuation approaches, which use significant unobservable inputs, or Level 3 inputs, as defined by the fair value hierarchy. Inputs to these valuation approaches require significant judgment including: (i) forecasted sales, growth rates and customer attrition rates, (ii) forecasted operating margins, (iii) royalty rates and discount rates used to present value future cash flows, (iv) the amount of synergies expected from the acquisition, (v) the economic useful life of assets and (vi) the evaluation of historical tax positions. In certain acquisitions, historical data is limited, therefore, we base our estimates and assumptions on budgets, business plans, economic projections, anticipated future cash flows and marketplace data.
In
relation with the purchase by SteriLumen, Inc., of Old SAM Partners, LLC, on March 31, 2022, there was a settlement of a dispute that
arose during the first quarter of 2022 between both parties regarding certain representations and warranties in the purchase agreement
which resulted in a settlement and mutual release agreement where the seller agreed to relinquish any right, title, and interest in the
previously issued shares.
During the three months ended March 31, 2022, the company recorded a loss on change in fair market value of contingent consideration
of $
On March 25, 2022, the Company entered into an asset purchase agreement by and among the Company, MunnWorks, LLC., a New York Limited Liability Company and wholly-owned subsidiary of the Company (the “Purchaser”) and VisionMark LLC, a New York limited liability company (the “Seller”), pursuant to which the Purchaser acquired substantially all of the assets of the Seller in exchange for the assumption of obligations of buyer under the sublease and sublease guarantee.
The purchase price and purchase price allocation as of the acquisition completion date follows.
| Schedule of recognized identified assets acquired and liabilities assumed | ||||
| Purchase Price: | ||||
| Cash paid at closing | $ | |||
| Due to landlord | ||||
| Total Purchase Price, net of cash acquired | ||||
| Assets Acquired: | ||||
| Accounts receivable, net | ||||
| Inventory | ||||
| Costs and estimated earnings in excess of billings | ||||
| Machinery and equipment | ||||
| Total Assets Acquired: | ||||
| Liabilities Assumed: | ||||
| Billings in excess of costs and earnings on uncompleted contracts | ( | ) | ||
| Net Assets Acquired | ||||
| Excess Purchase Price "Goodwill" | $ | |||
| 14 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 2 – BUSINESS ACQUISITION (CONTINUED)
The
excess purchase price has been recorded as goodwill in the amount of approximately $
In
connection with the VisionMark LLC acquisition, the Company is obligated to repay $
As of March 31, 2023, the future maturity of the lease liability is as follows:
| Schedule of future maturity of the lease liability | ||||
| Years Ended December 31, | ||||
| 2023 (9 months) | $ | |||
| 2024 | ||||
| 2025 | ||||
| Total | ||||
| Less: Unamortized discount | ( | ) | ||
| Total amount due to landlord | ||||
| Less: current portion of amount due to landlord, net of discount | ( | ) | ||
| Total long-term portion of amount due to landlord | $ | |||
On
January 26, 2023, the Company entered into an asset purchase agreement by the Company (the "Buyer") and PURO Lighting, LLC, (the
"Seller") a limited liability company under the laws of the State of Colorado, pursuant to which the Purchaser acquired substantially
all of the assets of the Seller in exchange for cash, common stock and preferred stock of the buyer. The Company paid or issued, as applicable
| 15 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 2 – BUSINESS ACQUISITION (CONTINUED)
The purchase price and purchase price allocation as of the acquisition completion date follows.
| Schedule of recognized identified assets acquired and liabilities assumed | ||||
| Purchase Price: | ||||
| Cash paid at closing, net of cash acquired | $ | |||
| Common stock | ||||
| Series B Preferred Stock | ||||
| Series C Preferred Stock | ||||
| Contingent consideration-Make Whole*** | ||||
| Contingent consideration-Earnout | ||||
| Total Purchase Price, net of cash acquired | ||||
| Assets Acquired: | ||||
| Accounts receivable, net | ||||
| Inventory | ||||
| Other current assets | ||||
| Fixed assets, net | ||||
| Tradenames/trademarks | ||||
| Technology/know-how/trade secrets | ||||
| Patented technology | ||||
| Customer relationships | ||||
| Total Assets Acquired: | ||||
| Liabilities Assumed: | ||||
| Accounts payable | ( | ) | ||
| Deferred revenue | ( | ) | ||
| Total Liabilities Assumed | ( | ) | ||
| Net Assets Acquired | ||||
| Excess Purchase Price "Goodwill" | $ | |||
| 16 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 2 – BUSINESS ACQUISITION (CONTINUED)
***Represents
the difference in fair value of common stock on the
The
excess purchase price has been recorded as goodwill in the amount of approximately $
On
January 26, 2023, the Company also entered into an asset purchase agreement by the Company (the "Buyer") and LED Supply Co, LLC,
(the “Seller”), a limited liability company under the laws of the State of Colorado, pursuant to which the Purchaser acquired
substantially all of the assets of the Seller in exchange for cash, common stock and preferred stocks of the buyer. The Company paid
or issued, as applicable
The purchase price and purchase price allocation as of the acquisition completion date follows.
| Schedule of recognized identified assets acquired and liabilities assumed | ||||
| Purchase Price: | ||||
| Cash paid at closing, net of cash acquired | $ | |||
| Common stock | ||||
| Series C Preferred Stock | ||||
| Contingent considerations - Make Whole*** | ||||
| Contingent considerations - Earnout | ||||
| Total Purchase Price, net of cash acquired | ||||
| Assets Acquired: | ||||
| Accounts receivable, net | ||||
| Inventory | ||||
| Other current assets | ||||
| Vendor deposits | ||||
| Costs and estimated earnings in excess of billings | ||||
| Fixed assets, net | ||||
| Tradenames/trademarks | ||||
| Technology/know-how/trade secrets | ||||
| Vendor relationships | ||||
| Rebate program | ||||
| Customer relationships | ||||
| Other non-current assets | ||||
| Total Assets Acquired: | ||||
| Liabilities Assumed: | ||||
| Accounts payable and accrued expenses | ( | ) | ||
| Deferred revenue | ( | ) | ||
| Notes payable | ( | ) | ||
| Financing lease liability | ( | ) | ||
| Total Liabilities Assumed | ( | ) | ||
| Net Assets Acquired | ||||
| Excess Purchase Price "Goodwill" | $ | |||
| 17 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 2 – BUSINESS ACQUISITION (CONTINUED)
***The
amount represents the difference in fair value of common stock on the
The
excess purchase price has been recorded as goodwill in the amount of approximately $
NOTE 3 – INVENTORY
Inventory consists of the following as of:
| Schedule of Inventory | ||||||||
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Raw materials | $ | $ | ||||||
| Finished goods | ||||||||
| Inventory at cost | ||||||||
| Less: Reserve | ( | ) | ( | ) | ||||
| Inventory | $ | $ | ||||||
NOTE 4 – PROPERTY AND EQUIPMENT
Property and equipment (including machinery and equipment under capital leases) are summarized by major classifications as follows:
| Schedule of property and equipment | ||||||||
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Machinery and Equipment | $ | $ | ||||||
| Leasehold improvements | ||||||||
| Furniture and Fixtures | ||||||||
| Less: Accumulated Depreciation | ( | ) | ( | ) | ||||
| $ | $ | |||||||
Depreciation
expense, including amortization of assets under Financing leases, for the three months ended March 31, 2023 and 2022 was $
| 18 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 5 – INTANGIBLE ASSETS
Intangible assets as of March 31, 2023 and December 31, 2022 consist of the following:
| Schedule of Intangible Assets | ||||||||
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Intangible assets subject to amortization | ||||||||
| Customer Relationships | $ | $ | ||||||
| Tradenames/trademarks | ||||||||
| Patented technology | ||||||||
| Technology/know-how/trade secrets | ||||||||
| Vendor relationships | ||||||||
| Rebate program | ||||||||
| Less: Accumulated Amortization | ( | ) | ( | ) | ||||
| $ | $ | |||||||
During
the three months ended March 31, 2023 and 2022, the Company recorded total amortization expense related to intangible assets of
$
Future amortization of intangible assets are as follows:
| Future amortization of intangible assets | |||||
| For the year ending December 31, | |||||
| 2023 (9 months) | $ | ||||
| 2024 | |||||
| 2025 | |||||
| 2026 | |||||
| Thereafter | |||||
| Total | $ | ||||
NOTE 6 – FINANCING LEASE OBLIGATION
The Company's future minimum principal and interest payments under a financing lease for machinery and equipment are as follows:
| Schedule of future minimum principal and interest payments under capital lease arrangements | ||||
| 2023 (9 months) | $ | |||
| 2024 | ||||
| 2025 | ||||
| 2026 | ||||
| 2027 | ||||
| Total lease payments | ||||
| Less: Amount representing interest | ( | ) | ||
| Present value of future minimum lease payments | ||||
| Less: current portion | ( | ) | ||
| Financing lease obligations, net of current | $ |
| 19 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 7 – NOTES PAYABLE
As of March 31, 2023 the Company had the following notes payable outstanding:
| Schedule of notes payable | ||||||||
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| Loan Agreement | $ | $ | ||||||
| Streeterville Note #1 | ||||||||
| Streeterville Note #2 | ||||||||
| Netsuite Cloud Services Financing Agreement | ||||||||
| Directors and Officers Liability Insurance Agreement | ||||||||
| Pinnacle Note | ||||||||
| Total | ||||||||
| Less: Unamortized debt discount | ( | ) | ( | ) | ||||
| Total notes payable | ||||||||
| Notes payable, current | ( | ) | ( | ) | ||||
| Notes payable, non current | $ | $ | ||||||
Minimum obligations under these loan agreements are as follows:
| Schedule of minimum obligations under loan agreement | |||||
2023 (nine months) | $ | ||||
| 2024 | |||||
| Total | $ |
Loan Agreement
The
Company entered into a loan agreement in April of 2019 where the company was required to pay $
Streeterville Note #1
On
October 7, 2022, the Company entered into a Security Purchase Agreement with Streeterville Capital, LLC whereby the Company issued an
The
lender has the right at any time 6 months after the effective date, at its election, to redeem all or part of the maximum redemption
amount as set forth in the promissory note. Payments of each redemption amount may be made (a) in cash, or (b) in common stock per the
following formula: the portion of the applicable Redemption amount being paid in common stock divided by the common stock redemption
price, or (c) by any combination of the foregoing. Whereas common stock redemption price means
| 20 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 7 – NOTES PAYABLE (continued)
Streeterville Note #1 (Continued)
The principal amount of the Note may be prepaid in full, or any portion of the outstanding balance earlier than it is due; provided that in the event borrower elects to prepay all or any portion of the outstanding balance it shall pay to lender 120% of the portion of the outstanding balance borrower elects to prepay. The prepayment premium will not apply if borrower repays the Note in full on the anniversary date, which is one year from the purchase price date.
If
prior to the anniversary date all redemption amounts are paid as common stock redemptions, then each time after the anniversary date
that borrower makes a common stock redemption, $
Debt
discount related to the note amounts to $
Interest
expense recorded in the accompanying Statements of Operations by the Company was $
Streeterville Note #2
On
January 25, 2023, the Company entered into a Security Purchase Agreement with Streeterville Capital, LLC whereby the Company issued an
| 21 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 7 – NOTES PAYABLE (continued)
Streeterville Notes (Continued)
The features and conditions relating to this note is similar with the Streeterville note issued on October 7, 2022.
Debt
discount recognized during 2023 related to the note amounts to $
Interest
expense recorded in the accompanying Statements of Operations by the Company was $
Netsuite Cloud Services Financing Agreement
On
November 1, 2022, PURO entered into a financing arrangement for $
Directors and Officers Liability Insurance Agreement
On
August 28, 2022, the Company entered into a one-year Directors and Officers Liability Insurance agreement for $
Pinnacle Note
In
December 2022, the Company entered into a Loan and Security Agreement, or (the “Loan Agreement”), with Pinnacle Bank, which
provides for a $
| 22 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 7 – NOTES PAYABLE (continued)
Pinnacle Note (Continued)
Obligations
under the Loan Agreement are secured by all the Company's assets. On the effective date the Company paid a loan fee of
The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and the Subsidiaries, including, without limitation, restrictions on liens, indebtedness, fundamental changes, capital expenditures, consignments of inventory and distributions.
The Loan Agreement contains customary events of default, including, without limitation, payment defaults, covenant defaults, breaches of certain representations and warranties, certain events of bankruptcy and insolvency, certain events under ERISA and judgments. If an event of default occurs and is not cured within any applicable grace period or is not waived, the Lender is entitled to take various actions, including, without limitation, the acceleration of amounts due thereunder and termination of commitments under the Loan Facility.
There
was a $
Chase Credit Facility
In
connection with the acquisition of LED Supply Co, LLC, the Company assumed $
NOTE 8 – FAIR VALUE MEASUREMENTS
Accounting guidance on fair value measurements requires that financial assets and liabilities be classified and disclosed in one of the following categories of the fair value hierarchy:
Level 1 – Based on unadjusted quoted prices for identical assets or liabilities in an active market.
Level 2 – Based on observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3– Based on unobservable inputs that reflect the entity’s own assumptions about the assumptions that a market participant would use in pricing the asset or liability.
| 23 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 8 – FAIR VALUE MEASUREMENTS (CONTINUED)
We did not have any transfers between levels during the periods presented.
The following table presents assets and liabilities that were measured at fair value in the Consolidated Balance Sheets on a recurring basis as of March 31, 2023 and December 31, 2022:
| Fair value, assets measured on recurring basis | ||||||||||||||||||||
| Carrying Amount | Fair Value | Quoted Priced in active markets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) | ||||||||||||||||
| As of March 31, 2023 | ||||||||||||||||||||
| Assets | ||||||||||||||||||||
| Money market funds | $ | $ | $ | $ | $ | |||||||||||||||
| Total assets | $ | $ | $ | $ | $ | |||||||||||||||
| Liabilities | ||||||||||||||||||||
| Contingent consideration | $ | $ | $ | $ | $ | |||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Total liabilities | $ | $ | $ | $ | $ | |||||||||||||||
| As of December 31, 2022 | ||||||||||||||||||||
| Assets | ||||||||||||||||||||
| Money market funds | $ | $ | $ | $ | $ | |||||||||||||||
| Total assets | $ | $ | $ | $ | $ | |||||||||||||||
| Liabilities | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Total liabilities | $ | $ | $ | $ | $ | |||||||||||||||
The carrying amounts of accounts receivable, accounts payable and short-term debt approximated fair values as of March 31, 2023 and December 31, 2022 because of the relatively short maturity of these instruments. There were no other level 3 or level 1 assets or liabilities as of March 31, 2023.
Money
market funds – Cash equivalents of $
Contingent consideration – The fair value of the contingent consideration related to the Make Whole is derived through the quoted market price of our stock, which represents a Level 1 measurement within the fair value hierarchy. As a result of the merger transaction, the company assumed an Earn-out liability, which is remeasured each reporting period. Given the unobservable nature of the inputs, the fair value measurement of the deferred earn-out is deemed to use Level 3 inputs. The Earn-out liability was accounted for as a liability as of the date of the merger transaction and will be remeasured to fair value until the Earnout Triggering Events are met.
Warrant liability – The fair value of the warrant liability is derived through the Black Scholes method and is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy.
| 24 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 8 – FAIR VALUE MEASUREMENTS (CONTINUED)
Other Fair Value Measurements
In addition to assets and liabilities that are recorded at fair value on a recurring basis, GAAP requires that, under certain circumstances, we also record assets and liabilities at fair value on a nonrecurring basis.
In connection with the acquisitions of VisionMark in 2022, and PURO Lighting and LED Supply Co. in 2023, as discussed in Note 2, we used various valuation techniques to determine fair value, with the primary techniques being discounted cash flow analysis and the relief-from-royalty, a form of the multi-period excess earnings, which use significant unobservable inputs, or Level 3 inputs, as defined by the fair value hierarchy.
NOTE 9 – STOCKHOLDERS' EQUITY
At the Market Sales Agreement
On
July 1, 2022, the Company filed a $
In
May 2023 the Company sold an additional ATM shares, with gross proceeds of $
Amendment of the Certificate of Designation
In relation to designated shares of the Company’s Series X Super Voting Preferred stock, on July 11, 2022, the Board of Directors approved the reissuance of 8,000 of these shares which represent the remainder of the designated but unissued shares of Super Voting Preferred Stock.
On March 9, 2022, the Board of Directors approved a resolution that authorized the senior management of the Company to purchase up to and limited to one million shares of common stock between March 10, 2022 and September 30, 2022. As of March 31, 2023, the Company has a total of treasury shares.
Pursuant to the Company’s amended and restated certificate of incorporation, as amended, the Company is authorized to designate and issue up to shares of preferred stock, par value $per share, in one or more classes or series. During the year ended December 31, 2022, the Company had preferred shares designated as Series X Preferred Stock and shares of preferred stock designated as 10.5% Series A Cumulative Perpetual Preferred Stock (the “Series A Preferred Stock”). As of March 31, 2023 the Company had preferred shares designated as Series B Preferred Stock, preferred shares designated as Series C Preferred Stock, preferred shares designated as Series X Preferred Stock, shares designated as 10.5% Series A Cumulative Perpetual Preferred Stock, and shares undesignated.
| 25 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 9 – STOCKHOLDERS' EQUITY (CONTINUED)
Preferred Stock, Series A Cumulative Perpetual
Holders are entitled to receive cumulative cash dividends at the annual rate of 10.5% on $25.00 liquidation preference per share of the Series A Perpetual Preferred Stock. Dividends accrue and are payable in arrears beginning August 15, 2021, regardless of whether declared or there are sufficient earnings or funds available for payment. Sufficient net proceeds from the offering must be set aside to pay dividends for the first twelve months from issuance. The Company has an optional redemption right beginning July 16, 2022, which redemption price declines annually. The initial redemption price after year 1 is $30 and decreases annually over 5 years to $25 per share. The Company also has a special optional redemption right upon the occurrence of a Delisting Event or Change of Control, as defined, at $25 per share plus accrued and unpaid dividends. The holders have no voting rights, except for voting on certain corporate decisions, or upon default in payment of dividends for any twelve periods, in which case the holders would have voting rights to elect two additional directors to serve on the Board of Directors. Such shares are not convertible unless and until the occurrence of a Delisting Event or Change of Control and when the Company has not exercised its special optional redemption right. The conversion price would be the lesser of the amount converted based on the $25.00 liquidation preference plus accrued dividends divided by the common stock price of the Delisting Event or Change of Control (as defined) or $5.353319 (Share Cap). Effectively, the Share Cap limits the common stock price to no lower than $4.67.
Preferred Stock, Series B Cumulative Perpetual
On
January 25, 2023, the Company filed the Certificate of Designations, Rights, and Preferences for the Series B Preferred Stock with the
Secretary of State of the State of Delaware, which became effective upon acceptance for record. On January 26, 2023, the Company filed
the Amendment to the Series B Certificate of Designation (together with the Certificate of Designations, Rights, and Preferences for
the Series B Preferred Stock, the “Series B Certificate of Designation”), which became effective upon acceptance for record.
The Series B Certificate of Designation classified a total of shares of the Company’s authorized shares
of preferred stock, $
Upon any voluntary or involuntary liquidation, dissolution, or winding up of the Corporation, before any distribution or payment shall be made to holders of shares of Common Stock or any other class or series of capital stock of the Corporation ranking, as to rights upon any voluntary or involuntary liquidation, dissolution, or winding up of the Corporation, junior to the Series B Preferred Stock, the holders of shares of Series B Preferred Stock shall be entitled to be paid out of the assets of the Corporation legally available for distribution to its stockholders, a liquidation preference of $per share, plus an amount equal to any accrued and unpaid dividends (whether or not authorized or declared) up to the date of payment. In the event that, upon such voluntary or involuntary liquidation, dissolution, or winding up, the available assets of the Corporation are insufficient to pay the full amount of the liquidating distributions on all outstanding shares of Series B Preferred Stock and the corresponding amounts payable on all shares of other classes or series of capital stock of the Corporation ranking, as to rights upon the Corporation's liquidation, dissolution, or winding up, on parity with the Series B Preferred Stock in the distribution of assets, then the holders of the Series B Preferred Stock and each such other class or series of capital stock ranking, as to rights upon any voluntary or involuntary liquidation, dissolution, or winding up, on parity with the Series B Preferred Stock shall share ratably in any such distribution of assets in proportion to the full liquidating distributions to which they would otherwise be respectively entitled. Written notice of any such voluntary or involuntary liquidation, dissolution, or winding up of the Corporation, stating the payment date or dates when, and the place or places where, the amounts distributable in such circumstances shall be payable, shall be given not fewer than thirty (30) days or more than sixty (60) days prior to the payment date stated therein, to each record holder of shares of Series B Preferred Stock at the respective addresses of such holders as the same shall appear on the stock transfer records of the Corporation. After payment of the full amount of the liquidating distributions to which they are entitled, the holders of Series B Preferred Stock will have no right or claim to any of the remaining assets of the Corporation. The consolidation, merger, or conversion of the Corporation with or into any other corporation, trust, or entity, or the voluntary sale, lease, transfer, or conveyance of all or substantially all of the property or business of the Corporation, shall not be deemed to constitute a liquidation, dissolution, or winding up of the Corporation.
| 26 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 9 – STOCKHOLDERS' EQUITY (CONTINUED)
Preferred Stock, Series C Cumulative Perpetual
On
January 25, 2023, the Company filed the Certificate of Designations, Rights, and Preferences for the Series C Preferred Stock with the
Secretary of State of the State of Delaware, which became effective upon acceptance for record. On January 26, 2023, the Company filed
the Amendment to the Series C Certificate of Designation (together with the Certificate of Designations, Rights, and Preferences for
the Series C Preferred Stock, the “Series C Certificate of Designation”), which became effective upon acceptance for record.
The Series C Certificate of Designation classified a total of shares of the Company’s authorized shares
of preferred stock, $
Upon any voluntary or involuntary liquidation, dissolution, or winding up of the Corporation, before any distribution or payment shall be made to holders of shares of Common Stock or any other class or series of capital stock of the Corporation ranking, as to rights upon any voluntary or involuntary liquidation, dissolution, or winding up of the Corporation, junior to the Series C Preferred Stock, the holders of shares of Series C Preferred Stock shall be entitled to be paid out of the assets of the Corporation legally available for distribution to its stockholders, after payment of or provision for the debts and other liabilities of the Corporation and any class or series of capital stock of the Corporation ranking, as to rights upon any voluntary or involuntary liquidation, dissolution, or winding up of the Corporation, senior to the Series C Preferred Stock, a liquidation preference of $per share, plus an amount equal to any accrued and unpaid dividends (whether or not authorized or declared) up to the date of payment. In the event that, upon such voluntary or involuntary liquidation, dissolution, or winding up, the available assets of the Corporation are insufficient to pay the full amount of the liquidating distributions on all outstanding shares of Series C Preferred Stock and the corresponding amounts payable on all shares of other classes or series of capital stock of the Corporation ranking, as to rights upon the Corporation's liquidation, dissolution, or winding up, on parity with the Series C Preferred Stock in the distribution of assets, then the holders of the Series C Preferred Stock and each such other class or series of capital stock ranking, as to rights upon any voluntary or involuntary liquidation, dissolution, or winding up, on parity with the Series C Preferred Stock shall share ratably in any such distribution of assets in proportion to the full liquidating distributions to which they would otherwise be respectively entitled. Written notice of any such voluntary or involuntary liquidation, dissolution, or winding up of the Corporation, stating the payment date or dates when, and the place or places where, the amounts distributable in such circumstances shall be payable, shall be given not fewer than thirty (30) days or more than sixty (60) days prior to the payment date stated therein, to each record holder of shares of Series C Preferred Stock at the respective addresses of such holders as the same shall appear on the stock transfer records of the Corporation. After payment of the full amount of the liquidating distributions to which they are entitled, the holders of Series C Preferred Stock will have no right or claim to any of the remaining assets of the Corporation. The consolidation, merger, or conversion of the Corporation with or into any other corporation, trust, or entity, or the voluntary sale, lease, transfer, or conveyance of all or substantially all of the property or business of the Corporation, shall not be deemed to constitute a liquidation, dissolution, or winding up of the Corporation.
| 27 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 9 – STOCKHOLDERS' EQUITY (continued)
A summary of the Company’s option activity and related information follows:
| Schedule of the Company’s option activity | ||||||||||||||||||||
| Number of Options | Weighted-Average Exercise Price | Weighted-Average Grant Date Fair Value | Weighted-Average Remaining Contractual Life (in years | Aggregate intrinsic value | ||||||||||||||||
| Balances, January 1, 2022 | $ | $ | $ | — | ||||||||||||||||
| Options granted | — | |||||||||||||||||||
| Options forfeited | ( | ) | — | |||||||||||||||||
| Options exercised | — | |||||||||||||||||||
| Balances, December 31, 2022 | $ | $ | $ | — | ||||||||||||||||
| Options granted | — | |||||||||||||||||||
| Options forfeited | ( | ) | — | |||||||||||||||||
| Options exercised | — | |||||||||||||||||||
| Balances, March 31, 2023 | $ | $ | $ | — | ||||||||||||||||
| Vested and Exercisable | $ | $ | — | |||||||||||||||||
Share-based compensation expense for options totaling $and $was recognized for the three months ended March 31, 2023 and 2022, respectively, based on requisite service periods.
The valuation methodology used to determine the fair value of the options issued during the year was the Black-Scholes option-pricing model. The Black-Scholes model requires the use of a number of assumptions including volatility of the stock price, the average risk-free interest rate, and the weighted average expected life of the options.
The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the options.
Estimated volatility is a measure of the amount by which the Company’s stock price is expected to fluctuate each year during the expected life of the award. The Company’s calculation of estimated volatility is based on historical stock prices of peer entities over a period equal to the expected life of the awards. The Company uses the historical volatility of peer entities due to the lack of sufficient historical data of its stock price.
As of March 31, 2023, there was $of total unrecognized compensation expense related to unvested employee options granted under the Company’s share-based compensation plans that is expected to be recognized over a weighted average period of approximately 2.65 years.
| 28 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 9– STOCKHOLDERS' EQUITY (continued)
The weighted average fair value of options granted, and the assumptions used in the Black-Scholes model during the three months ended March 31, 2023 and 2022 are set forth in the table below.
| Schedule of share-based payment award, stock options, valuation assumptions | ||||||||
| 2023 | 2022 | |||||||
| Risk-free interest rate | % to % | % to % | ||||||
| Volatility | % to % | % to % | ||||||
| Expected life (years) | - | - | ||||||
| Dividend yield | % | % | ||||||
Common Stock Warrants
A summary of the Company’s warrant activity and related information follows:
| Schedule of the Company's warrant activity | ||||||||
| Number of Options | Weighted-Average Exercise Price | |||||||
| Balances, January 1, 2022 | $ | |||||||
| Granted | ||||||||
| Exercised | ||||||||
| Balances, December 31, 2022 | $ | |||||||
| Granted | ||||||||
| Exercised | ||||||||
| Balances, March 31, 2023 | $ | |||||||
| At March 31, 2023 | ||||||||
| Vested and Exercisable | $ | |||||||
| 29 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 9 – STOCKHOLDERS' EQUITY (continued)
In
relation to the common stock offering that was closed last December 28, 2021, on January 5, 2022, the underwriters fully exercised their
over-allotment option to purchase an additional shares of common stock at the public offering
price of $per share. The Company received gross proceeds
of $
Restricted Stock Awards
The Company records compensation expense for restricted stock awards based on the quoted market price of our stock at the grant date and the expense is amortized over the vesting period. These restricted stock awards are subject to time-based vesting conditions based on the continued service of the restricted stock award holder.
The following table presents the restricted stock units activity from January 1, 2022 through March 31, 2023:
| Schedule of unvested restricted stock units activity | ||||||||
| Number of Shares | Weighted-Average Fair Market Value | |||||||
| Unvested shares at January 1, 2022 | $ | |||||||
| Granted and unvested | ||||||||
| Vested | ( | ) | ||||||
| Forfeited/Cancelled | ( | ) | ||||||
| Unvested shares, December 31, 2022 | $ | |||||||
| Granted and unvested | ||||||||
| Vested | ( | ) | ||||||
| Forfeited/Cancelled | ( | ) | ||||||
| Unvested shares, March 31, 2023 | $ | |||||||
| Vested as of March 31, 2023 | $ | |||||||
Upon vesting, the restricted stock units are converted to common shares. Based on the terms of the restricted share and restricted stock unit grants, all forfeited shares revert back to the Company.
In connection with the grant of restricted shares, the Company recognized $and $of compensation expense within its statements of operations for the three months ended March 31, 2023 and 2022, respectively.
An additional shares of restricted stock were issued on April 19, 2023, as compensation for consulting expenses.
| 30 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 10 - LEASING ARRANGEMENTS
The Company determines whether an arrangement qualifies as a lease under ASC 842 at inception. The Company has operating leases for office space and office equipment. The Company’s leases have remaining lease terms of one year to seven years, some of which include options to extend the lease term for up to five years. The Company considered these options to extend in determining the lease term used to establish the Company’s right-of use assets and lease liabilities once reasonably certain of exercise. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and operating lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The operating lease ROU asset also includes any lease payments made in advance of lease commencement and excludes lease incentives. The lease terms used in the calculations of the operating ROU assets and operating lease liabilities include options to extend or terminate the lease when the Company is reasonably certain that it will exercise those options. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
As
the Company’s leases do not provide an implicit rate, the Company uses an incremental borrowing rate of
MunnWorks, LLC entered into a lease agreement in Mount Vernon, New York for a term that commenced on April 1, 2019 and will expire on the 31st day of March 2024 at a monthly rate of $13,400. In March of 2021, the Company obtained additional lease space and the agreement was amended to increase rent expense to $15,000 per month. On July 1, 2021, the Company again obtained additional lease space and rent expense was increased to $27,500 per month through July 1, 2024 and $29,150 per month from July 1, 2024 through July 1, 2026.
On September 28, 2021, the Company entered into a lease agreement in Kennesaw, Georgia for office and production space for a term that commenced on September 29, 2021 and will expire on October 1, 2024, with a rate ranging from $14,729 to $15,626 per month.
On April 1, 2022, the Company entered into a lease agreement in Brooklyn, New York for office and production space that commenced on April 1, 2022 and will expire on June 1, 2023, with a rate ranging from $94,529 to $97,365 per month. On December 31, 2022, the Company exercised its option to renew the first renewal term, commencing on July 1, 2023 and ending on June 30, 2025. As a result of the extension of the lease, the Company recorded an additional $2,146,785 of ROU asset and liability on the balance sheet on December 31, 2022.
On
January 26, 2023, the Company entered into a lease agreement in Lakewood, Colorado for office and production space that commenced on
January 27, 2023 and will expire on
Rent
expense for the three months ended March 31, 2023 and 2022 was $
Schedule maturities of operating lease liabilities outstanding as of March 31, 2023 are as follows:
| Schedule of maturities of operating lease liabilities | ||||
| 2023 (9 months) | $ | |||
| 2024 | ||||
| 2025 | ||||
| Thereafter... | ||||
| Total lease payments | ||||
| Less: Imputed Interest | ( | ) | ||
| Present value of future minimum lease payments | $ |
| 31 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 10 - LEASING ARRANGEMENTS (CONTINUED)
Consistent with ASC 842-20-50-4, the Company calculated its total lease cost based solely on its monthly rent obligation. The Company had no cash flows arising from its lease, no finance lease cost, short term lease cost, or variable lease costs. The Company’s lease does not produce any sublease income, or any net gain or loss recognized from sale and leaseback transactions. As a result, the Company did not need to segregate amounts between finance and operating leases for cash paid for amounts included in the measurement of lease liabilities, segregated between operating and financing cash flows; supplemental non-cash information on lease liabilities arising from obtaining right-of-use assets; weighted-average calculations for the remaining lease term; or the weighted-average discount rate.
NOTE 11 - SEGMENT REPORTING
FASB Codification Topic 280, Segment Reporting, establishes standards for reporting financial and descriptive information about an enterprise’s reportable segments. The Company has two reportable segments: the design, manufacture, assembly and distribution of disinfecting systems for use in healthcare, hospitality, and commercial municipal and residential markets (disinfectant segment) and the manufacture of fine mirrors specifically for the hospitality industry (hospitality segment). The segments are determined based on several factors, including the nature of products and services, the nature of production processes, customer base, delivery channels and similar economic characteristics.
An operating segment’s performance is evaluated based on its pre-tax operating contribution, or segment income. Segment income is defined as net sales less cost of sales, segment selling, general and administrative expenses, research and development costs and stock-based compensation. It does not include other charges (income), net and interest and other, net.
| Schedule of segment reporting | |||||||||||||||||
| Hospitality | Disinfection/Healthy Building Technologies | Corporate | Total | ||||||||||||||
| Balance sheet at March 31, 2023 | |||||||||||||||||
| Assets | $ | $ | $ | $ | |||||||||||||
| Liabilities | $ | $ | $ | $ | |||||||||||||
| Balance sheet at December 31, 2022 | |||||||||||||||||
| Assets | $ | $ | $ | $ | |||||||||||||
| Liabilities | $ | $ | $ | $ | |||||||||||||
| 32 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 11 - SEGMENT REPORTING (CONTINUED)
| Hospitality | Disinfection/Healthy Building technologies | Corporate | Total | |||||||||||||
| Income Statement for the three months ended March 31, 2023: | ||||||||||||||||
| Net Sales | $ | $ | $ | $ | ||||||||||||
| Cost of Goods Sold | $ | $ | $ | $ | ||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| Stock based compensation | $ | $ | $ | $ | ||||||||||||
| Income Statement for the three months ended March 31, 2022: | ||||||||||||||||
| Net Sales | $ | $ | $ | $ | ||||||||||||
| Cost of Goods Sold | $ | $ | $ | $ | ||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| Stock based compensation | $ | $ | $ | $ | ||||||||||||
| Loss on impairment of goodwill | $ | $ | $ | $ | ||||||||||||
| Selling, General and Administrative expenses | $ | $ | $ | $ | ||||||||||||
| 33 |
Applied UV, Inc. and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
NOTE 12 – PROFORMA FINANCIAL STATEMENTS (UNAUDITED)
Unaudited Supplemental Pro Forma Data
Unaudited pro forma results of operations for the three months ended March 31, 2023 and 2022 as though the company acquired Akida, KES, VisionMark, SciAir, PURO, and LED (the “Acquired Companies”) on January 1, 2022 is set forth below.
| Business acquisition, pro forma information | ||||||||
| Three Months Ended March 31, | ||||||||
| 2023 | 2022 | |||||||
| Net Sales | $ | $ | ||||||
| Net Loss | $ | ( | ) | $ | ( | ) | ||
| Net Loss attributable to common stockholders: | ||||||||
| Dividends to preferred shareholders | ( | ) | ( | ) | ||||
| Net Loss attributable to common stockholders | ( | ) | ( | ) | ||||
| Basic and Diluted Loss Per Common Share | $ | ( | ) | $ | ( | ) | ||
| Weighted Average Shares Outstanding - basic and diluted | ||||||||
NOTE 13 – SUBSEQUENT EVENTS
On
May 1, 2023 the Company entered into an agreement to amend certain terms in its redeemable promissory notes with Streeterville Capital,
LLC which were previously issued on October 7, 2022 and January 24, 2023. The amendment to the notes makes the accrued interest incurred
from these notes part of the principal balance of the note. The new principal balances for the 2022 and 2023 notes are $
Amortization of the amended notes begin on September 7, 2023 for the 2022 note and September 24, 2023 for the 2023 note.
| 34 |
ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Certain statements made in this prospectus are “forward-looking statements” regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the “Company” to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Company’s plans and objectives are based, in part, on assumptions involving the continued expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and therefore, there can be no assurance the forward-looking statements included in this prospectus will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Risk Factors” and in other parts of this prospectus. Our fiscal year ends on December 31.
Overview
Applied UV, Inc. (“AUVI”) is a leading sales and marketing company that develops, acquires, markets and sells proprietary surface and air disinfection technology focused on Improving Indoor Air Quality (IAQ), specialty LED lighting and luxury mirrors and commercial furnishings, all of which serves clients globally in the healthcare, commercial & public venue, hospitality, food preservation, cannabis, education, and winery vertical markets.
With its established strategic manufacturing partnerships and alliances including Canon, Acuity, Johnson Controls, USHIO, Siemens, Grainger, and a global network of 89 dealers and distributors in 52 countries, 47 manufacturing representatives, and 19 US based internal sales representatives, AUVI offers a complete suite of products through its four wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”), Munn Works, LLC (“MunnWorks”), PURO Lighting, LLC (‘PURO Lighting’), and LED Supply Co. LLC (“LED Supply Co.).
SteriLumen owns, brands, and markets a portfolio of research backed and clinically proven products utilizing advanced UVC Carbon, Broad Spectrum UVC LED’s, and Photo-catalytic oxidation (PCO) pathogen elimination technology, branded as Airocide ™, Scientific Air™, Airoclean™ 420, Lumicide™, PUROAir, PUROHealth, PURONet, and LED Supply Company. Sterilumen’s proprietary platform suite of patented surface and air technologies offers one of the most complete pathogen disinfection platforms including mobile, fixed, and HVAC systems and software solutions interconnecting its entire portfolio suite into the IoT, allowing customers to implement, manage and monitor IAQ measures recommended by the EPA across any enterprise. Additionally, the Lumicide™ platform applies the power of ultraviolet light (UVC) to destroy pathogens automatically, addressing the challenge of healthcare-acquired infections ("HAI’s) in several patented designs for infection control in healthcare. LED Supply Company is a full-service, wholesale distributor of LED lighting and controls throughout North America. MunnWorks manufactures and sells custom luxury and backlit mirrors, conference room and living spaces furnishings.
Our global list of Fortune 100 end users including Kaiser Permanente, NY Health+Hospitals, MERCY Healthcare, University of Chicago Medical, Baptist Health South Florida, New York City Transit, Samsung, JB Hunt, Boston Red Sox’s Fenway Park, JetBlue Park, France’s Palace of Versailles, Whole Foods, Del Monte Foods, U.S. Department of Veterans Affairs, Marriott, Hilton, Four Seasons and Hyatt, and more. For information on Applied UV, Inc., and its subsidiaries, please visit https://www.applieduvinc.com
According to Research and Markets, the UV Disinfection market is expected to reach $9 billion by 2027 as technology continues to improve and the focus on stopping the spread of contagious diseases increases. The Center for Disease Control states that 1 in 25 patients have at least one Hospital Associated Infection (HAI) annually and that 3 million serious infections occur every year in long-term care facilities. Losses from contagious infections, pathogens, and viruses cost the U.S. economy more than $270B every year as per the CDC: $28B lost through HAI’s; $225B in lost productivity due to absenteeism; and $25B in losses due to Student/Teacher absenteeism. Scientists globally have been advocating improving air quality post pandemic, significantly boosting global adoption to control airborne pathogen transmission. Governments globally mandating health agencies to address improving indoor air quality (IAQ) via grants and mechanisms to ease visitation and protect facilities against future pathogens (Centers for Medicare and Medicaid Services – CMS, February 2022 Long-term Care Initiative April 2022 White House Clean Air Initiatives).
Indoor air quality (IAQ) has become an even more important issue as world economies transition beyond the COVID 19 pandemic. In 2021, 39 scientists reiterated the need for a "paradigm shift" and called for improvements in, "how we view and address the transmission of respiratory infections to protect against unnecessary suffering and economic losses." In mid-2022 we began to see this seismic shift from pandemic related mobile apparatuses to complete systems within systems for facilities designed to monitor, improve, and report on a more permanent basis. While there are opportunities for mobile systems, our emphasis will be on this growing market trend.
| 35 |
In addition to this, the global air purifier market size is set to grow exponentially. It was valued at $9.24 billion in 2021 and is predicted to grow to approximately $22.84 billion by 2030. According to Precedence Research, the immense demand for air purification and sterilization in the US will be driven by the commercial sector.
Sterilumen’s product portfolio is one of the only research-backed, clinically proven pure-play air and surface disinfection technology companies with international distribution and globally recognized end users, with product developed for NASA. In addition to the numerous recognized research institutions and globally recognized names who published the reports that were completed by the acquired companies, Airocide was independently proven to kill SARS, MERSA and Anthrax. Sterilumen’s air purification (Airocide, Scientific Air & PURO Lighting) and surface disinfection (Lumicide) were independently tested and proven to kill both Candida Auris (Resinnova Laboratories) and SARS CoV-2 (COVID-19) (MRIGlobal), MRSA (Resinnova Laboratories), Salmonella enterica (Ressinnova Laboratories) and Escherichia coli (Resinnova Laboratories).
Our goal is to build a company that successfully designs, develops, and markets our air and surface disinfection solutions that will enable US and global economies to implement “Clean Air” initiatives aimed at improving indoor air quality (IAQ) as recommended by the US Government’s EPA. We will seek to achieve this goal by having our products actively involved in the following activities:
Focus on key target verticals that have proven business use cases including:
▪ Food Preservation
• Post-Harvest and Distribution/Logistics from ”farm-to-table”
▪ Healthcare
• Hospitals, Long-Term Care, Dental
▪ Food and Beverage
• Winery, Dairy, Meat & Seafood
▪ Hospitality
• Hotels, Restaurants
▪ Education
• Public/Non-Public Schools and Universities
▪ Public Spaces
• Sports Arenas, Office Buildings (HVAC)
▪ Cannabis
▪ Correctional Facilities
In addition to further developing Airocide, Scientific Air, PURO, Lumicide and LED Supply specific sales efforts, we intend to leverage the Company’s hospitality business (MunnWorks) for cross-selling opportunities of our air purification and surface disinfectant solutions and products. Our initial research indicates that the key stakeholders in this market value the asset management and reporting capabilities of our platform and provide key points of differentiation.
| • | Expand our global distributor channels into new markets not currently served. |
| • | Continue scientific validation through lab testing and data from real world deployments; publish case studies in peer reviewed journals. |
| 36 |
Manufacturing
In an effort to improve operationally, after analyzing each of the points in our supply chain to tighten integration to optimize inventory, improve quality control, and mitigate against supply chain disruptions that were witnessed globally throughout the pandemic, on December 18th, 2022, Applied UV announced that it has signed a strategic manufacturing and related services agreement with Canon Virginia, Inc., (“CVI”) a global manufacturing, engineering and technical operation for the Canon family and a wholly owned subsidiary of Canon U.S.A, Inc. The agreement establishes CVI’s status as the primary manufacturer, assembler, and logistical authority for Applied UV’s entire suite of air purification solutions. The Manufacturing Agreement, the first of a series of anticipated agreements, enables the Company to leverage the resources of CVI’s two million-square-foot state-of-the-art engineering, manufacturing, and distribution facility. Applied UV plans to leverage CVI’s almost 40 years of innovative and efficient production methods to manufacture the Company’s patented, FDA Class II Listed Airocide PCO commercial and consumer devices, as well as the patented advanced Activated Carbon UVC and HEPA Mobile disinfection Scientific Air portfolio. From an R&D perspective, working closely with Canon, we are also beginning to formulate our new product roadmap and making substantial improvements to our entire line of mobile and fixed air purification products, further differentiating our patented PCO and UVC Carbon based solutions from that of our competition. Applied UV also plans to collaborate with Canon Financial Services, Inc. to enable better cash flow management in regard to its growing supply chain requirements. Further, the Company will look to work with CVI’s extensive field support team to promote the sale of the Company’s products, as well as service capabilities.
MunnWorks is a manufacturer of custom designed fine mirrors and furniture specifically for the hospitality industry with one manufacturing facility in Mount Vernon, New York and, with the acquisition of the assets of VisionMark, another manufacturing facility in Brooklyn, New York. Our goal is to contribute to the creation of what our design industry clients seek: manufacturing better framed mirrors and customized furniture on budget and on time. As part of our long-term strategy, the Company has instituted multi-site production for high-value items, complicated designs and finishes. Our headquarters in Mount Vernon, NY serves as the center for multi-country manufacturing. The Company works with a satellite network of artisans and craftsmen, including gilders, carvers, and old-world finishers.
Acquisitions
Air Disinfection Solutions & LED Lighting: Airocide, Scientific Air, PURO and LED Supply Co.
The Airocide™ system of air purification technologies, originally developed for the National Aeronautics and Space Administration (“NASA”) with assistance from the University of Wisconsin at Madison, uses a combination of UVC and a proprietary, titanium dioxide based photocatalyst to eliminate airborne bacteria, mold, fungi, viruses, volatile organic compounds and many odors. The core Airocide™ technology has been in use on the International Space Station and is based on photo-catalytic oxidation (PCO), a bioconversion process that continuously converts damaging molds, microorganisms, dangerous pathogens, destructive volatile organic chemicals (VOCs) and biological gasses into harmless water vapor. Unlike other air purification systems that provide “active” air cleaning, ozone producing systems, ionization or “photo-electrochemical oxidation”, Airocide’s™ nanocoating technology permanently bonds titanium dioxide to the surface of the catalytic bed. This permits the perpetual generation of surface-bound (OH-) radicals over the large surface area created by their advanced geometric design and prevents the generation and release of ozone and other harmful byproducts. The proprietary formulation and methods for creating the catalyst are the basis of Airocide’s™ competitive advantage, making it the only consistently robust, highly effective, ozone free PCO technology on the market. Airocide™ has been tested over the past 12 years by governmental agencies such as NASA, the National Renewable Energy Laboratory, independent universities including the University of Wisconsin, Texas Tech University, and Texas A&M, as well as air quality science laboratories. Airocide™ technology is listed as a FDA Class II Medical Device, making it a suitable for providing medical grade air purification in critical hospital use cases. Airocide™ Product lines include APS (consumer units), the GCS and HD lines (commercial units that will include the Sterilumen App to bring connectivity, reporting and asset management to our suite of products). The APS series provides true choice, low maintenance filter-less PCO or a filtered PCO air purification option ideal for restaurants, conference rooms, residential and small business or home office spaces. The GCS series is suitable for larger public spaces and enclosed rooms that may have high occupancy such as offices, waiting rooms and hotel lobbies, and airport gate areas. The HD series is the most powerful, providing two-stage purification for fast sanitization of larger or industrial spaces such as sporting venues and locker rooms, airports, museums, winery cellars, warehouses, and food-processing facilities. All Airocide™ products also extend the life of any perishables like fruit, produce or flowers.
On October 13, 2021, we acquired substantially all of the assets of Old SAM Partners, LLC F/K/A Scientific Air Management, LLC (“Old SAM”), which owned a line of air purification technologies (“Scientific Air”). The Scientific Air product line uses a combination of UVC and a proprietary, patented system to eliminate airborne bacteria, mold, fungi, viruses, volatile organic compounds, and many odors without producing any harmful by-products. Scientific Air’s products are well suited for larger spaces within a facility due to the higher air flow of these units. The units are also mobile with industrial grade casters, allowing for movement throughout a facility to address increased bio burden from larger meetings or increased human traffic. Both of these key items extend our Airocide line, creating a comprehensive air disinfection portfolio that spans from small to large spaces and mobile applications. Scientific Air’s products are currently sold predominantly in North America and into the healthcare market.
| 37 |
PURO Lighting
On January 26, 2023 we closed on the merger agreement with PURO Lighting LLC and LED Supply Co. LLC along with its operating subsidiaries (“PURO merger”). PURO Lighting LLC and LED Supply Co. own a powerful suite of products used in education, government, and healthcare that incorporates UV Lighting and a HVAC monitoring software platform; LED Supply Co. provides design, distribution, and implementation services for lighting, controls and smart building technologies.
PURO Lighting was founded in 2019 with the goal of using light technology to promote health and wellness within spaces. Today PURO provides a suite of UV disinfection systems that have the ability to disinfect air and surfaces in commercial and industrial spaces. They focus their sales efforts in three primary verticals: Education, Government, and Healthcare. The acquisition of PURO Lighting, LLC adds PUROHealth and PURONet - a powerful suite of products used in education, government, and healthcare that incorporates UV Lighting and a HVAC monitoring software platform. With its UL listed and patented portfolio of independently tested (Resonova Labs) synergistic surface and air disinfection technologies that help facility managers protect against multiple pathogens; PURO opens new opportunities for cross marketing sales to existing distribution channels. Additionally, the potential to inter-connect our entire portfolio of disinfection technology solutions into the IoT will provide our customers with both products and smart tools to manage and monitor indoor air quality (IAQ) across any enterprise. Applied UV’s proprietary platform suite of patented technologies offers the most complete pathogen disinfection platform including mobile, fixed and HVAC systems and solutions allowing companies to implement the IAQ measures recommended by the EPA. PURO boast a strong domestic sales network with reps in 43 states, and distribution in all 50 states. Their product offerings encompass a range of innovative solutions, including UVC systems for air handling, in-room continuous disinfection using cutting-edge Far-UVC technology, and specialized surface disinfection solutions designed specifically for the healthcare industry.
The PURO Acquisition further positions the Company to address a growing air disinfection market trend that aligns with the White House “Clean Air Initiatives” implemented during the height of the COVID 19 Pandemic designed to protect consumers and businesses against existing and future airborne pathogens allowing economies globally to remain open. The merged entities have proven applications that can now be included in improving indoor air quality (IAQ) at the facility level including HVAV systems in public, government, municipal, retail spaces and buildings. The PURO Acquisition positions Applied UV to be one of the only companies in the world to offer a complete air and surface disinfection platform that includes consumer, fixed and mobile, and commercial applications that are research backed, clinically tested and that are used by global Fortune 100 end users in multiple verticals.
LED Supply Company
Founded in 2009, LED Supply Company is a national, Colorado-based company that provides design, distribution, and implementation services for lighting, controls and smart building technologies. LED Supply Co continues to expand its market reach with a focus on new types of energy efficiency and sustainable technologies. Along with its robust e-commerce component, LED Supply Company has recently taken the next step in revenue growth by repositioning itself as a preferred supplier for not only the latest in LED technologies, but the source for emerging technologies and product categories that the construction and retrofit market need; from electric vehicle charging to smart home technology, emergency and safety equipment, and much more.
We see synergies across our entire air and surface disinfection/healthy building technologies portfolio. First, we look to leverage Airocide’s global distribution capabilities to facilitate the sale of Scientific Air’s and PURO’s offerings internationally. Second, we look to leverage PURO’s strength in healthcare to pull through existing Airocide™ units, creating a broad healthcare product line, from small clinics, patient rooms and doctor’s offices to larger spaces such as nursing stations, waiting rooms and cafeterias. Third, we look to leverage the national MunnWorks hospitality reach with leading luxury hotel chain operators to pull through our entire air and surface disinfection/healthy building technologies portfolio (Airocide™ and Lumicide™) as well as PURO’s offerings into future hotel, condo and other renovation, upgrade and remodeling projects. Fourth, the Company will look to work with Canon Virginias’ (CVI) extensive field support team to promote the sale of the Companys’ products as well as service capabilities. Finally, we look to incorporate the PUROAir, PUROHealth and PURONet (a powerful suite of products used in healthcare that incorporates UV Lighting and a HVAC monitoring software platform) into our IoT integration plans via the Teralumen App across our entire platform connecting all our units, thereby creating a leading smart asset management, reporting, and control system tool that can be incorporated across all enterprises.
Principal Factors Affecting Our Financial Performance
Our operating results are primarily affected by the following factors:
| • | our ability to acquire new customers or retain existing customers. |
| • | our ability to offer competitive product pricing. |
| • | our ability to broaden product offerings. |
| • | industry demand and competition; and |
| • | market conditions and our market positions. |
| 38 |
Results of Operations
| Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | |||||||||||||||||||||||||||||||
| Hospitality | Disinfection/Healthy Building Technologies | Corporate | Total | Hospitality | Disinfection/Healthy Building Technologies | Corporate | Total | |||||||||||||||||||||||||
| Net Sales | $ | 6,081,373 | $ | 4,573,110 | $ | — | $ | 10,654,483 | $ | 1,409,250 | $ | 1,946,840 | $ | — | $ | 3,356,090 | ||||||||||||||||
| Cost of Goods Sold | 5,306,186 | 3,425,911 | — | 8,732,097 | 1,158,644 | 1,048,347 | — | 2,206,991 | ||||||||||||||||||||||||
| Gross Profit | 775,187 | 1,147,199 | — | 1,922,386 | 250,606 | 898,493 | — | 1,149,099 | ||||||||||||||||||||||||
| Research and development | — | 189,210 | — | 189,210 | — | 59,314 | — | 59,314 | ||||||||||||||||||||||||
| Stock based compensation | 56,854 | 36,176 | 96,585 | 189,615 | 86,011 | 22,286 | 179,702 | 287,999 | ||||||||||||||||||||||||
| Loss on impairment of goodwill | — | — | — | — | — | 1,138,203 | — | 1,138,203 | ||||||||||||||||||||||||
| Selling, General and Administrative | 1,033,589 | 2,883,973 | 1,157,202 | 5,074,764 | 659,087 | 1,785,210 | 368,930 | 2,813,227 | ||||||||||||||||||||||||
| Total Operating expenses | 1,090,443 | 3,109,359 | 1,253,787 | 5,453,589 | 745,098 | 3,005,013 | 548,632 | 4,298,743 | ||||||||||||||||||||||||
| Operating Loss | (315,256 | ) | (1,962,160 | ) | (1,253,787 | ) | (3,531,203 | ) | (494,492 | ) | (2,106,520 | ) | (548,632 | ) | (3,149,644 | ) | ||||||||||||||||
| Other Income | ||||||||||||||||||||||||||||||||
| Change in Fair Market Value of Warrant Liability | — | — | 2,302 | 2,302 | — | — | 43,828 | 43,828 | ||||||||||||||||||||||||
| Interest expense | — | — | (392,939 | ) | (392,939 | ) | (4,102 | ) | — | 46 | (4,056 | ) | ||||||||||||||||||||
| Gain on settlement of contingent consideration | — | — | — | — | — | — | 1,700,000 | 1,700,000 | ||||||||||||||||||||||||
| Loss on change in contingent consideration | — | — | (619,999 | ) | (619,999 | ) | — | — | (240,000 | ) | (240,000 | ) | ||||||||||||||||||||
| Total Other Income (Expense) | — | — | (1,010,636 | ) | (1,010,636 | ) | (4,102 | ) | — | 1,503,874 | 1,499,772 | |||||||||||||||||||||
| Loss Before Provision for Income Taxes | (315,256 | ) | (1,962,160 | ) | (2,264,423 | ) | (4,541,839 | ) | (498,594 | ) | (2,106,520 | ) | 955,242 | (1,649,872 | ) | |||||||||||||||||
| Provision for Income Taxes | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||
| Net Loss | $ | (315,256 | ) | $ | (1,962,160 | ) | $ | (2,264,423 | ) | $ | (4,541,839 | ) | $ | (498,594 | ) | $ | (2,106,520 | ) | $ | 955,242 | $ | (1,649,872 | ) | |||||||||
| Non-GAAP Financial Measures | ||||||||||||||||||||||||||||||||
| Adjusted EBITDA | ||||||||||||||||||||||||||||||||
| Operating Loss | $ | (315,256 | ) | $ | (1,962,160 | ) | $ | (1,253,787 | ) | $ | (3,531,203 | ) | $ | (494,492 | ) | $ | (2,106,520 | ) | $ | (548,632 | ) | $ | (3,149,644 | ) | ||||||||
| Depreciation and Amortization | 57,463 | 603,313 | — | 660,776 | 7,975 | 459,771 | — | 467,746 | ||||||||||||||||||||||||
| Loss on impairment of goodwill | — | — | — | — | — | 1,138,203 | — | 1,138,203 | ||||||||||||||||||||||||
| Stock based compensation | 56,854 | 36,176 | 96,585 | 189,615 | 86,011 | 22,286 | 179,702 | 287,999 | ||||||||||||||||||||||||
| Adjusted EBITDA | $ | (200,939 | ) | $ | (1,322,671 | ) | $ | (1,157,202 | ) | $ | (2,681,083 | ) | $ | (400,506 | ) | $ | (486,260 | ) | $ | (368,930 | ) | $ | (1,255,696 | ) | ||||||||
| 39 |
The Company utilizes Adjusted EBITDA, a non-GAAP financial measure, to assist in analyzing our segment operating performance by removing the impact of certain key items that management believes do not directly reflect our underlying operations. In addition, we consider certain non-GAAP (or "adjusted") measures to be useful to management and investors evaluating our operating performance for the periods presented, and provide a tool for evaluating our ongoing operations, liquidity, and management of assets. This information can assist investors in assessing our financial performance and measures our ability to generate capital. These adjusted metrics are consistent with how management views our business and are used to make financial, operating and planning decisions. These metrics, however, are not measures of financial performance under GAAP and should not be considered a substitute for revenues, operating income, net income (loss), earnings (loss) per share (basic and diluted) or net cash from operating activities as determined in accordance with GAAP. Adjusted EBITDA is defined as Operating Profit (Loss), excluding Depreciation and Amortization, and excluding Stock Based Compensation and Loss on Impairment of Goodwill/Intangible Assets. Adjusted EBITDA was a loss of $2.7 million for the three months ended March 31, 2023, which was an increase of $1.4 million as compared to the three ended March 31, 2022. By segment, Hospitality decreased $0.2 million, Disinfection/Healthy Building Technologies increased $0.8 million, and Corporate increased $0.8 million.
Segments
The Company has three reportable segments: the design, manufacture, assembly and distribution of disinfecting pathogen elimination systems for use in food preservation, healthcare, hospitality, education and public spaces, cannabis, correctional facilities, and commercial, municipal and residential markets (Disinfection/Healthy Building Technologies segment); the manufacture of fine mirrors and custom furniture specifically for the hospitality industry (Hospitality segment); and the Corporate Segment, which includes expenses primarily related to corporate governance, such as board fees, legal expenses, audit fees, executive management, and listing costs. See NOTE 11 – Segment Reporting.
Net Sales
Net sales of $10.7 million represented an increase of $7.3 million, or 217.5% for the three months ended March 31, 2023 as compared to net sales of $3.4 million for the three months ended March 31, 2022. This increase was primarily attributable to the Hospitality segment, which increased $4.7 million, largely as a result of the strategic acquisition on March 25, 2022 of the operations of VisionMark in Brooklyn, NY, which contributed $3.9 million of the increase, and also due to the organic growth of our legacy MunnWorks business, which contributed $0.8 million of the increase. The Disinfection/Healthy Building Technologies segment increased $2.6 million, primarily due the acquisition of PURO Lighting and LED Supply Co. on January 26, 2023.
Gross Profit
Gross profit increased $0.8 million from $1.1m, or 34% vs. sales, for the three months ended March 31, 2022 to $1.9m, or 18% vs. sales for the three months ended March 31, 2023. The decrease from 34% to 18% was driven primarily by the higher sales mix of our Hospitality segment as compared to the same period last year. For Q1 2023, Hospitality accounted for 57% of total sales for the quarter as compared to 42% in the prior year quarter. The last of the lower margin projects that we acquired that were in process from the VisionMark asset acquisition have been substantially completed. Additionally, Q1 2023 was impacted by “one-time” lower margins in our Disinfection/Healthy Building Technologies segment as we sold approximately half of our consumer Airocide inventory at special discounted pricing.
Operating Expenses
Selling, General, and Administrative – S,G&A costs for the three months ended March 31, 2023, increased to $5.1 million as compared to $2.8 million for the three months ended March 31, 2022. This increase of $2.3 million was driven primarily by the expansion of the Disinfection/Healthy Building Technologies segment with the acquisitions of PURO Lighting and LED Supply Co. These acquisitions accounted for $1.4 million of the increase. In Corporate, legal expenses increased $0.6 million primarily as the result of a “one-time” arbitration case.
Loss on Impairment of Goodwill – In the first quarter of 2022, the Company had determined that a triggering event had occurred as a result of a settlement agreement with Scientific Air (“Old SAM Partners”) - see explanation of Other Income/Expense below. A quantitative impairment test on the goodwill determined that the fair value was below the carrying value and as a result the Company recorded a full goodwill impairment charge of $1.1 million on the Condensed Consolidated Statements of Operations during the three months ended March 31, 2022.
Operating Loss
The Company recorded an operating loss of $3.5 million for the three months ended March 31, 2023, compared to an operating loss of $3.1 million for the three months ended March 31, 2022. The increase of $0.4 million in the operating loss was primarily due to the decrease in the gross profit percentage year over year as explained above, and the impairment charge of $1.1 million that was incurred last year. On a percentage basis, the operating loss improved to 33% in the first quarter of 2023 as compared to 94% in the first quarter of 2022.
Other Income/Expense
The Company incurred interest expense of $0.4 million due to the borrowings of Streeterville Capital and Pinnacle Bank., primarily to help fund the acquisitions of PURO Lighting and LED Supply Co. and to also fund additional working capital requirements.
The Company incurred a non-cash loss on change in fair market value of contingent consideration of $0.6 million because of the make whole provision within the PURO Lighting and LED Supply Co. merger agreement. The change related to the decrease in our stock price from the date of acquisition of January 26, 2023 as compared to March 31, 2023.
| 40 |
On March 31, 2022, there was a dispute between the Company and Scientific Air (“Old SAM Partners”) regarding certain representations and warranties in the purchase agreement which resulted in a settlement and mutual release agreement where Old Sam Partners agreed to relinquish such Partner’s right, title, and interest in the previously issued 400,000 shares that were part of the original asset acquisition transaction. The Company recorded a loss on change in fair market value of contingent consideration of $0.24 million, and as a result of the settlement, the company recorded a gain on settlement of $1.7 million during the three months ended March 31, 2022.
Net Loss
The Company recorded a net loss of $4.5 million for the three months ended March 31, 2023, compared to a net loss of $1.6 million for the three months ended March 31, 2022. The increase of $2.9 million in the net loss was mainly due to the $1.4 million increase in S,G&A costs incurred as a result of the acquisitions of PURO Lighting and LED Supply Co. in support of the expansion to the Disinfection/Healthy Building Technologies segment; the $0.6 million increase in Corporate legal expenses largely as a result of a “one-time” arbitration case and the non-cash loss on change in fair market value of contingent consideration of $0.6 million because of the make whole provision within the PURO Lighting and LED Supply Co. merger agreement (see comment above in Other Income/Expense).
Liquidity and Capital Resources
Three Months Ended March 31, 2023 Compared to the Three Months Ended March 31, 2022
| Net Cash Used in Operating Activities | $ | (3,269,645 | ) | $ | (1,858,793 | ) | ||
| Net Cash Used in Investing Activities | (4,274,799 | ) | (16,793 | ) | ||||
| Net Cash Provided by Financing Activities | 6,891,845 | 728,012 | ||||||
| Net Decrease in cash and cash equivalents | (652,599 | ) | (1,147,574 | ) | ||||
| Cash and equivalents at beginning of period | 2,734,485 | 8,768,156 | ||||||
| Cash and equivalents at end of period | 2,081,886 | 7,620,582 |
In the three months ended March 31, 2023, net cash used in operating activities was $3.3 million, as compared to $1.9 million in the three months ended March 31, 2022. This increase in net cash used was due mainly to the increase in net loss of $2.9 million, from $1.6 million in Q1 2022 to $4.3 million in Q1 2023. Additionally, after adjusting for the acquisitions of PURO Lighting and LED Supply Co., accounts receivable decreased $1.4 million, which was offset by an increase in accounts payable of $2.1 million.
In the three months ended March 31, 2023, net cash used in investing activities decreased to $4.3 million primarily due to net cash paid of $4.1 million for the acquisitions of PURO Lighting and LED Supply Co. on January 26, 2023.
In the three months ended March 31, 2023, cash provided by financing activities was $6.9 million, as compared to cash provided by financing activities of $0.7 million in the three months ended March 31, 2022. The increase of $6.2 million is primarily due to our borrowings on our Streeterville Capital note and on our Pinnacle Bank credit facility. The Company also raised net proceeds $2.3 million through its ATM facility with Maxim Group with 1,818,214 shares sold. In the first quarter of 2022, the Company raised $1.1 million through the full exercise of their common stock offering over-allotment.
On July 1, 2022, the Company filed a $50,000,000 mixed use shelf registration (Form S-3) and entered into an At The Market sales agreement ("ATM") with Maxim Group, LLC for a total of $9,000,000, as a readily available source of funding if needed. During the year ended December 31, 2022, the Company sold 804,811 ATM shares through the sales agent with gross proceeds of $964,083. In connection with the sale of these ATM Shares, the compensation paid by the Company to the Sales Agent was $28,922. As of March 31, 2023, an additional 1,764,311 shares have been sold for gross proceeds of $2,314,860, and the compensation paid by the Company to the Sales Agent was $69,446, leaving a balance of $5,721,057 on the ATM facility. The shelf registration statement will expire on July 12, 2025.
The Company has filed a Registration Statement with the Securities and Exchange Commission with its plans to commence a public offering of its securities for an amount that satisfies the Company’s’ current working capital needs.
The Company believes our sources of liquidity and capital will be sufficient to finance our continued operations and growth strategy.
| 41 |
Contractual Obligations and Other Commitments
| Payment due by period | ||||||||||||||||||||
| Total | 2023 | 2024-2026 | 2027-2028 | Thereafter | ||||||||||||||||
| Financing lease obligations | 243,120 | 47,949 | 159,062 | 36,109 | — | |||||||||||||||
| Operating lease obligations (1) | 4,125,692 | 1,279,211 | 2,846,481 | — | — | |||||||||||||||
| Notes payable (2) | 157,500 | 127,500 | 30,000 | — | — | |||||||||||||||
| D&O Insurance Loan (3) | 83,131 | 83,131 | ||||||||||||||||||
| Streeterville notes (4) | 5,615,000 | 3,156,270 | 2,458,730 | — | — | |||||||||||||||
| Pinnacle loan (5) | 4,351,040 | 4,351,040 | — | — | ||||||||||||||||
| Netsuite Financing Agreement (6) | 180,258 | 67,599 | 112,659 | — | — | |||||||||||||||
| Assumed lease liability (7) | 6,972,173 | 1,279,211 | 2,846,481 | 2,846,481 | — | |||||||||||||||
| Total | 21,727,914 | 6,040,871 | 12,804,453 | 2,882,590 | — | |||||||||||||||
| (1) | The Company entered into a lease agreement in Mount Vernon, New York for a term that commenced on April 1, 2019 and expires on the 31st day of March 2024 at a monthly rate of $15,000. On July 1, 2021, the Company obtained additional lease space and rent expense was increased to $27,500 per month through July 1, 2024 and $29,150 per month from Jul 1, 2024 through July 1, 2026. On September 28, 2021, the Company entered into a lease agreement in Kennesaw, Georgia for a term that commenced on September 29, 2021 and will expire on October 1, 2024, with monthly payments ranging from approximately $14,700 to $15,600 per month. On April 1, 2022, the Company entered into a lease agreement in Brooklyn, New York for office and production space that commenced on April 1, 2022 and will expire on June 1, 2023, with monthly payments ranging from approximately $94,500 to $97,400 per month. |
| (2) | In March 2020, as part of the On-Deck Capital settlement, the Company issued a promissory note for the principal amount of $157,500 due within the next 5 years. The Company is required to pay $157,500 in five payments in the amount of $30,000 per year, with an additional $7,500 in year two. |
| (3) | On August 28, 2022, the Company entered into a one-year Directors and Officers Liability Insurance agreement for $318,833. Under the terms of the agreement, the Company made a down payment of $41,730, with the remaining balance financed over the remaining term at an annual percentage rate of 5.05%. Beginning in September 2022, the Company is making 10 monthly payments of $27,710, with the last payment expected to be made in June 2023. |
| (4) | On October 7, 2022 and January 25, 2023, the Company entered into a Security Purchase Agreement with Streeterville Capital, LLC whereby the Company issued 8% unsecured redeemable notes in the principal amount of $2,807,500 and $2,807,500, respectively. The notes mature 18 months from the original issuance date. |
| (5) | In December 2022, the Company entered into a Loan and Security Agreement, or (the “Loan Agreement”), with Pinnacle Bank, which provides for a $5,000,000 secured revolving credit facility (the “Loan Facility”). The loan is subject to a maximum advance rate of up to 85% of net face amount of eligible accounts, plus the lessor a) of the sum of 20% of the aggregate eligible inventory value of raw materials and 35% of the aggregate eligible inventory value of finished goods, b) $1 million, c) 80% of the net orderly liquidation value of raw materials and finished goods, or d) 100% of the aggregate outstanding principal amount of advances. In no event shall the aggregate amount of the outstanding advances under the Loan Facility be greater than $5 million. The loan matures on December 9, 2024. The principal amount of outstanding revolving loan, together with accrued and unpaid interest, is due on the maturity date. |
| (6) | On November 1, 2022, PURO entered into a financing arrangement for $225,323 to finance its NetSuite cloud services. The Company is required to pay $7,511 per month through April 1, 2025. The liability was assumed in connection with the business combination on January 26, 2023. As of March 31, 2023, the outstanding balance of the financing agreement was $180,258. |
| (7) | In connection with the VisionMark LLC acquisition, the Company is obligated to repay $31,057 of prior lease payments per month for the next 36 months commencing on April 1, 2022. |
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.
| 42 |
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Not applicable.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of March 31, 2023. Based on that evaluation, the Company’s Chief Executive Officer and the Company’s Chief Financial Officer have concluded that as of March 31, 2022, due to the existence of the material weakness in the Company’s internal control over financial reporting described below, the Company’s disclosure controls and procedures were not effective.
Evaluation of Disclosure Controls and Procedures
Our Chief Financial Officer is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers, or persons performing similar functions, and effected by our Board, senior management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We continue to review our internal control over financial reporting and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.
Under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in “Internal Control — Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on the control deficiencies identified during this evaluation and set forth below, our senior management has concluded that we did not maintain effective internal control over financial reporting as of March 31, 2023 due to the existence of a material weakness in internal control over financial reporting as described below.
As set forth below, management will continue to take steps to remediate the control deficiencies identified below. Notwithstanding the control deficiencies described below, we have performed additional analyses and other procedures to enable management to conclude that our consolidated financial statements included in this Form 10-Q fairly present, in all material respects, our financial condition and results of operations as of and for the three months ended March 31, 2023.
A material weakness is a deficiency, or a combination of deficiencies, in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
The Company’s management has developed a remediation plan to address the material weakness and as of January 1, 2021 began using a new cloud-based software which tracks the progress of jobs and more accurately reflects the percentage of job completeness ensure such revenue is recognized in the appropriate period. In addition, the Company intends to further remediate the deficiency by performing the following:
| • | design and implement additional internal controls and policies to ensure that we routinely review and document our application of established significant accounting policies; and |
| • | implement additional systems and technologies to enhance the timeliness and reliability of financial data within the organization. |
| • | continue to engage third-party subject matter experts to aid in identifying and applying US GAAP rules related to complex financial instruments as well as to enhance the financial reporting function. |
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control procedures over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during our fiscal quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| 43 |
PART II – OTHER INFORMATION
Item 1. Legal Proceedings
None.
Item 1A. Risk Factors
The Company is a smaller reporting company and therefore not required to provide the information required by this item.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None
Item 3. Defaults Upon Senior Securities.
None
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None
Item 6. Exhibits
EXHIBIT INDEX
* Filed herewith
** Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.
| 44 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| APPLIED UV, INC. | ||
| (Registrant) | ||
| Date: May 22, 2023 | By: | /s/ Max Munn |
| Max Munn | ||
| Chief Executive Officer | ||
| Date: May 22, 2023 | By: | /s/ Michael Riccio |
| Michael Riccio | ||
| Chief Financial Officer | ||
| 45 |